Recent findings illuminate the potential benefits of BIO 300, an oral suspension aimed at improving lung function in COVID-19 patients following hospital discharge. Results from a Phase 2 clinical trial, conducted by Humanetics Corporation, underscore the drug's ability to significantly enhance
Dengue fever, a mosquito-borne viral disease, affects millions of people worldwide, particularly in tropical and subtropical regions. This debilitating illness is transmitted by infected Aedes mosquitoes, leading to severe symptoms and complications for many afflicted individuals. Despite the high
Boehringer Ingelheim has made significant strides in their research on progressive pulmonary fibrosis (PPF) with the successful results of their Phase III FIBRONEER™-ILD trial. This trial marks a critical milestone for Nerandomilast, an investigational oral preferential inhibitor of
The recent Orphan Drug Designation (ODD) granted by the U.S. Food and Drug Administration (FDA) to Zai Lab Limited for their drug ZL-1310 marks a significant milestone in the fight against small cell lung cancer (SCLC). This promising Delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC) is
The recent FDA Fast Track designation for BR55, developed by Bracco Imaging, marks a significant milestone in the diagnostic imaging industry. This novel molecular imaging ultrasound contrast agent specifically targets vascular endothelial growth factor receptor 2 (VEGFR2), a receptor highly
Sangamo Therapeutics, Inc., a leading genomic medicine company, has reported promising updated data from the Phase 1/2 STAAR study. This study explores the efficacy of isaralgagene civaparvovec (ST-920) as a treatment for Fabry disease. The analysis, which reflects data up to September 12, 2024,
